ITMCTR2100005333尚未招募1 期
A multicenter, randomized controlled, double-blind and double simulated clinical evaluation of gandouling tablet in the treatment of patients with hepatolenticular degeneration
The First Affiliated Hospital of Anhui University of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 15 至 85(—)
- 性别
- All
入选标准
- •(1) Comply with the diagnosis of hepatolenticular degeneration Guidelines for Diagnosis and Treatment of Hepatolenticular Degeneration 2021; the diagnosis of TCM syndromes complies with the syndrome of phlegm and blood stasis; Other copper-removing drugs; (3) Patients who have been treated with complexing agents for copper-removing treatment can enter the study after a 2-week washout period; (4) Age =15 years; (5) Informed consent of patients or legal representatives, And sign the informed consent form.
排除标准
- •(1) Severe cerebral WD patients: obvious torsion spasm, dysphagia, or bed rest and other severe neurological impairment will interfere with the safety of the subjects (UWDRS Part I neurological function score =156 points); (2) Severe liver Type WD patients: Decompensated liver cirrhosis or liver cancer, manifested as portal hypertension, ascites, splenomegaly (WBC<3.0*109/L, PLT<50*1012/L), esophageal varices, gastrointestinal bleeding, Moderate to severe anemia or hepatic encephalopathy; severe liver fibrosis shown by imaging or any laboratory abnormality (UWDRS liver function score = 17 points); (3) moderate to severe depression, recent suicidal thoughts or behavior, Severe psychiatric symptoms (UWDRS Part III Psychiatric Symptom Score = 54 points); (4) History of epileptic seizures within 6 months; (5) Complicated with serious diseases such as brain tumors, brain trauma, blood diseases, Cardiogenic diseases, HIV, etc.; (6) Nephritis, nephrotic syndrome, or kidney disease stage 3 or more; (7) Pregnant, planned pregnancy or breastfeeding women; (8) Cognitive dysfunction MMSE=26 points; (9) Those who are currently participating in other clinical trials; (10) Cannot comply with the follow-up plan.
研究者
相似试验
招募中
2 期
A multicenter randomized, controlled, double-blinded trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitisG04Encephalitis, myelitis and encephalomyelitisautoimmune encephalitisDRKS00017497Friedrich-Schiller-Universität Jena50
尚未招募
1 期
A multicenter, double-blind, randomized controlled trial on the effect of DLTM Formula on the progression of coronary calcification in patients with stable coronary heart diseaseITMCTR2024000060Xiyuan Hospital, China Academy of Chinese Medical Sciences
进行中(未招募)
1 期
A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune EncephalitisMedDRA version: 20.0Level: PTClassification code: 10072378Term: Encephalitis autoimmune Class: 100000004852autoimmune encephalitisCTIS2024-514494-21-00Friedrich-Schiller-Universitaet Jena50
已完成
不适用
A randomized, double-blind, controlled multicenter trial for availability of carbon dioxide insufflation during ERCP for reduction of postprocedure paipancreaticobiliary diseaseJPRN-UMIN000003062Department of Gastroenterology, Hokkaido University Graduate School of Medicine100
已完成
不适用
A double-blind, randomised, controlled multicentre trial of three misoprostol regimens after pretreatment with mifepristone for termination of early pregnancyPregnancy and ChildbirthAbortionInduced abortionISRCTN81170837DP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction (HRP)2,100
